XENETIC BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
XENETIC BIOSCIENCES, INC. (XBIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.88 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2020-03-26
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2019 was $1.88M, a 10.77% increase from fiscal 2018.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2018 was $1.70M.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2017 was -$359.83K, a 103.69% decline from fiscal 2016.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2016 was $9.75M, a 335.55% increase from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2019-12-31 | $1.88M 10-K · filed 2020-03-26 |
| 2018-12-31 | $1.70M 10-K · filed 2020-03-26 |
| 2017-12-31 | -$359.83K 10-K · filed 2019-03-29 |
| 2016-12-31 | $9.75M 10-K · filed 2018-03-30 |
| 2015-12-31 | $2.24M 10-K · filed 2017-03-31 |
| 2014-12-31 | $4.95M 10-K · filed 2016-03-30 |
| 2013-12-31 | $1.46M 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |